奥利司他对结直肠癌SW40细胞系中OCT4、Nanog、SOX2和KLF4基因表达的影响评估

Evaluation of the Effect of Orlistatorlistat on Expression of OCT4, Nanog, SOX2, and KLF4 Genes in Colorectal Cancer SW40 Cell Line.

作者信息

Noroozi Karimabad Mojgan, Roostaei Farzad, Mahmoodi Mehdi, Hajizadeh Mohammad Reza

机构信息

Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

出版信息

Asian Pac J Cancer Prev. 2021 Aug 1;22(8):2335-2341. doi: 10.31557/APJCP.2021.22.8.2335.

DOI:10.31557/APJCP.2021.22.8.2335

PMID:34452543

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8629468/

Abstract

BACKGROUND AND OBJECTIVE

Orlistat drug is one of the most criticalanti-obesity drugs that widely used around the world. The aim of this study was evaluation the effect of orlistat on the expression of OCT4, Nanog, SOX2, and KLF4 genes in the colorectal cancer SW40 cell line.

MATERIALS AND METHODS

SW40 cell line was cultured in DMEM medium contained orlistat for 24h, and cell viability was assessed by MTT assay. The fold changes of expression of OCT4, NANOG, KLF4, and SOX2 at mRNA level against β-actin were determined by real-timePCR. Two-sample t-test and one-way ANOVA were used to compare the mean of expression of different genes in different groups and different concentrations; a significant level of 0.05 was considered in all tests.

RESULTS

Our results showed a significant difference in cell viability, when different doses of Orlistat were used for 24 hour. concentrations of 25 and 100 μM reduce significantly the expression of OCT4 (p <0.05) and SOX2 (p <0.05) in the treated group in comparison to control (p <0.05). Also, the mRNA expression of KLF4 and Nanog was reduced significantly after treatment of SW40 cell lines was performed with 100 μM doses of Orlistat (p <0.05).

CONCLUSION

It appears that after further studies in animal and human phases, orlistat can be used for the treatment of Colorectal Cancer.
.

摘要

背景与目的

奥利司他药物是全球广泛使用的最关键的抗肥胖药物之一。本研究的目的是评估奥利司他对结直肠癌SW40细胞系中OCT4、Nanog、SOX2和KLF4基因表达的影响。

材料与方法

将SW40细胞系在含有奥利司他的DMEM培养基中培养24小时，通过MTT法评估细胞活力。通过实时PCR测定OCT4、NANOG、KLF4和SOX2在mRNA水平相对于β-肌动蛋白的表达倍数变化。采用两样本t检验和单因素方差分析比较不同组和不同浓度下不同基因表达的平均值；所有测试均采用0.05的显著性水平。

结果

我们的结果显示，当使用不同剂量的奥利司他处理24小时时，细胞活力存在显著差异。与对照组相比，25和100μM浓度显著降低了处理组中OCT4（p<0.05）和SOX2（p<0.05）的表达。此外，用100μM剂量的奥利司他处理SW40细胞系后，KLF4和Nanog的mRNA表达也显著降低（p<0.05）。